Literature DB >> 7495809

Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a).

B R Gabel1, M I Koschinsky.   

Abstract

We have analyzed the proteolytic activity of a recombinant form of apolipoprotein(a) [r-apo-(a)]. A mutant 17-kringle from of r-apo(a) was engineered that contained a serine to arginine substitution which reinstates the tissue-type plasminogen activator (tPA) as determined by SDS-PAGE and fluorography and by Western blot analysis. However, tPA cleavage did not result in an active protease as both wildtype r-apo(a) and the mutant, either free or incorporated into r-Lp(a) particles, were uniformly inactive against a variety of chromogenic serine protease tripeptide substrates. To assess whether the large number of kringle IV repeats present in apo(a) inhibits proteolytic activity, we generated truncated forms of the Ser-->Arg proteolytic activity, we generated truncated forms of the Ser-->Arg mutant containing one or 10 kringle IV repeats. These truncated versions of r-apo(a) were susceptible to cleavage by tPA but were inactive against the plasmin substrate S-2251. Treatment of the Ser-->Arg mutant of the 17-kringle r-apo(a) with tPA and diisopropylflurophosphate (DFP) did not result in modification of the mutant protease domain by DFP. Finally, we incubated r-apo(a) or r-Lp(a) particles formed in vitro with purified human LDL; no degradation of LDL was observed after 16 h at 37 degrees C. The results of this study suggest that one or more of the substitutions present in the protease domain of apo(a), in addition to the Arg-->Ser substitution, render apo(a) proteolytically inactive.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495809     DOI: 10.1021/bi00048a023

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 2.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 3.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

4.  Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Authors:  Rocco Romagnuolo; Corey A Scipione; Michael B Boffa; Santica M Marcovina; Nabil G Seidah; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2015-03-16       Impact factor: 5.157

5.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

Review 6.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2015-12-08       Impact factor: 5.922

7.  Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Authors:  Rocco Romagnuolo; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2014-01-29       Impact factor: 5.922

8.  Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway.

Authors:  Taewoo Cho; Yoojin Jung; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2008-09-05       Impact factor: 5.157

9.  Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.

Authors:  Daniel I Chasman; Dov Shiffman; Robert Y L Zee; Judy Z Louie; May M Luke; Charles M Rowland; Joseph J Catanese; Julie E Buring; James J Devlin; Paul M Ridker
Journal:  Atherosclerosis       Date:  2008-07-26       Impact factor: 5.162

10.  Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Authors:  Santica M Marcovina; Noémie Clouet-Foraison; Marlys L Koschinsky; Mark S Lowenthal; Allen Orquillas; Michael B Boffa; Andrew N Hoofnagle; Tomáš Vaisar
Journal:  Clin Chem       Date:  2021-03-01       Impact factor: 12.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.